BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22969994)

  • 1. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I.
    Ito G; Tanaka H; Ohira M; Yoshii M; Muguruma K; Kubo N; Yashiro M; Yamada N; Maeda K; Sawada T; Hirakawa K
    Exp Ther Med; 2012 Jun; 3(6):925-930. PubMed ID: 22969994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer.
    Tanaka H; Muguruma K; Ohira M; Kubo N; Yamashita Y; Maeda K; Sawada T; Hirakawa K
    Anticancer Res; 2012 Aug; 32(8):3427-33. PubMed ID: 22843926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of PSK on recurrence of stage II/III gastric cancer].
    Tanaka H; Muguruma K; Kubo N; Amano R; Noda E; Yamada N; Yashiro M; Maeda K; Sawada T; Ohira M; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2258-60. PubMed ID: 21224540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients.
    Akagi J; Baba H
    Int J Clin Oncol; 2010 Apr; 15(2):145-52. PubMed ID: 20229169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer].
    Nakazato H; Koike A; Ichihashi H; Saji S; Danno M; Ogawa N
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2563-76. PubMed ID: 2505682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
    Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
    J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Nakazato H; Koike A; Saji S; Ogawa N; Sakamoto J
    Lancet; 1994 May; 343(8906):1122-6. PubMed ID: 7910230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1).
    Namikawa T; Fukudome I; Ogawa M; Munekage E; Munekage M; Shiga M; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Eur J Surg Oncol; 2015 Jun; 41(6):795-800. PubMed ID: 25887287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [[Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supported by the Ministry of Health and Welfare (Kondo's group])].
    Imaizumi M; Kondo T; Kamei H; Ichihashi H
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2397-403. PubMed ID: 2124433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein-bound polysaccharide K prolonged overall survival in gastric cancer patients from a non-Japanese Asian country who received gastrectomy and adjuvant chemotherapy.
    Wang TY; Chen CY; Huang TH; Yang YH; Chen KJ; Chou WC; Lu CH
    Medicine (Baltimore); 2022 Jul; 101(29):e29632. PubMed ID: 35866836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy.
    Fisher M; Yang LX
    Anticancer Res; 2002; 22(3):1737-54. PubMed ID: 12168863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer.
    Maehara Y; Inutsuka S; Takeuchi H; Baba H; Kusumoto H; Sugimachi K
    Cancer Chemother Pharmacol; 1993; 33(2):171-5. PubMed ID: 8261578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years.
    Niimoto M; Hattori T; Tamada R; Sugimachi K; Inokuchi K; Ogawa N
    Jpn J Surg; 1988 Nov; 18(6):681-6. PubMed ID: 3150019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.
    Yokoe T; Iino Y; Takei H; Horiguchi J; Koibuchi Y; Maemura M; Ohwada S; Morishita Y
    Anticancer Res; 1997; 17(4A):2815-8. PubMed ID: 9252721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU.
    Takahashi Y; Mai M; Nakazato H
    Anticancer Res; 2005; 25(2B):1377-84. PubMed ID: 15865094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polysaccharide K and Coriolus versicolor extracts for lung cancer: a systematic review.
    Fritz H; Kennedy DA; Ishii M; Fergusson D; Fernandes R; Cooley K; Seely D
    Integr Cancer Ther; 2015 May; 14(3):201-11. PubMed ID: 25784670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
    Miyake Y; Nishimura J; Kato T; Ikeda M; Tsujie M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Surg Today; 2018 Jan; 48(1):66-72. PubMed ID: 28634730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Efficacy by Addition of Protein-bound Polysaccharide K to Adjuvant Chemotherapy for Advanced Gastric Cancer.
    Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
    Anticancer Res; 2016 Aug; 36(8):4237-41. PubMed ID: 27466538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of immunochemotherapy with PSK, a protein-bound polysaccharide, in colorectal cancer and changes of tumor marker.
    Kudo S; Tanaka J; Kashida H; Tamegai Y; Endo S; Yamano HO
    Oncol Rep; 2002; 9(3):635-8. PubMed ID: 11956642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).
    Yoshinaga K; Saeki H; Oki E; Morita M; Ikeda T; Sugimachi K; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Soejima Y; Kawanaka H; Mimori K; Watanabe M; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Dec; 104(12):549-58. PubMed ID: 24693683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.